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Although conditioned inhibition of fear (or learned
safety) is a learning process critical for preventing
chronic stress, a predisposing factor for depression
and other psychopathologies, little is known about
its functional purposes or molecular mechanisms.
To obtain better insight into learned safety, we inves-
tigated its behavioral and molecular characteristics
and found that it acts as a behavioral antidepressant
in two animal models. Learned safety promotes the
survival of newborn cells in the dentate gyrus of
the hippocampus, while its antidepressant effect is
abolished in mice with ablated hippocampal neuro-
genesis. Learned safety also increases the expres-
sion of BDNF in the hippocampus and leads to
downregulation of genes involved in the dopaminer-
gic and neuropeptidergic but not the serotonergic
system in the basolateral amygdala. These data
suggest that learned safety is an animal model of
a behavioral antidepressant that shares some neuro-
nal hallmarks of pharmacological antidepressants
but is mediated by different molecular pathways.
INTRODUCTION
Instinctive and learned fear are essential for survival and are
evolutionarily conserved in organisms ranging from simple inver-
tebrates to mammals. In humans, pathological forms of learned
fear are hallmarks of severe psychopathologies such as anxiety
disorders, posttraumatic stress disorders, and depression. The
fact that fear can be enhanced through learning and can become
a symptom of psychopathology in humans suggests that this
form of learning may not always be appropriate and might, in
certain situations, lead to unfavorable consequences. Therefore,
it seems likely that effective inhibitory constraints exist that
prevent the inappropriate expression of learned fear.
In search for such a mechanism, Robert Rescorla extended
the early work of Ivan Pavlov and delineated ‘‘conditioned
inhibition’’ as a learning paradigm whereby a neutral CSdevelops the ability to inhibit responses to learned predictors
of aversive or rewarding stimuli (Pavlov, 1927; Rescorla, 1969).
Fear conditioning results from a positive correlation (pairing) of
a previously neutral CS and an aversive US. During conditioned
inhibition, by contrast, a CS that is negatively correlated (explic-
itly unpaired) with an aversive US becomes a positive signal
(predictor) for safety and reduces the expression of conditioned
fear. Since the animal associates the target signal with protec-
tion from an impending aversive event, conditioned inhibition
has been thought to represent a form of learned safety, a process
by which the animal learns to take advantage of sources of safety
and security in the environment (Candido et al., 2004; Dinsmoor,
2001; Wiertelak et al., 1992). The term ‘‘safety signal’’ generally
refers to a stimulus that is inversely or negatively correlated to
an aversive event (Candido et al., 2004). In our previous study,
we referred to learned safety as the learning and memory result-
ing from a conditioned inhibition training procedure (Rogan et al.,
2005). We here attempt to first characterize some of the behav-
ioral consequences of learned safety and then to go on to
explore it at the molecular level.
The ability to identify events that afford relief from ongoing
strain is thought to be crucial for the prevention of chronic stress,
a precipitating factor for the development of anxiety disorders
and depression (Chan et al., 2001; Davis and Shi, 1999; LeDoux,
1993; Rogan et al., 2001). This led us to investigate whether
learned safety, as a predictor of a break from continuously immi-
nent, stress-producing danger, may have antidepressant ef-
fects. We tested this idea in mice using the forced-swim test and
the unpredictable chronic mild stress (UCMS) paradigm. We
then assessed whether learned safety could also share some
major neuronal characteristics of pharmacological antidepres-
sant treatments, specifically modulation of neurogenesis and the
expression of BDNF in the dentate gyrus of the hippocampus
(Warner-Schmidt and Duman, 2006; Dranovsky and Hen, 2006;
Malberg and Duman, 2003).
The amygdala is a key structure for the pathogenesis of the
dominant emotional symptoms in major depression. To examine
the molecular mechanisms contributing to learned safety using
Affymetrix high-density oligonucleotide arrays, we focused on
the basolateral nucleus, the subregion of the amygdala where
we have previously described distinct electrophysiological
features of learned safety (Rogan et al., 2005).Neuron 60, 149–161, October 9, 2008 ª2008 Elsevier Inc. 149
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Behavioral Antidepressant Therapy in MiceFigure 1. Learned Safety Induces Reduction of Contextual Fear and Retards Subsequent Fear Conditioning to the Same Stimulus
(A) Safety conditioning consists of a simple conditioned inhibition of learned fear paradigm in which the delivery of four shock US is followed by the presentation of
four tone CS. In the fear conditioning protocol, the number of CS and US presentations is matched to the safety conditioning paradigm (four paired CS-US).
Training is conducted over a period of 3 days, one session per day. A memory recall test, consisting of a single CS presentation, is carried out 24 hr after the
last training day.
(B) Contextual freezing in the presence of the CS (n = 10–14 per group) (main effect of type of training [i.e., learned safety, learned fear, or tone-alone control]:
F(2,31) = 34.813, p < 0.001; effect of interaction between type of training and phase of testing [i.e., pre-CS or CS]: F(2,31) = 24.715, p < 0.001; Tukey-Kramer post hoc
test for type of training [CS phase]: safety versus fear and safety versus tone p < 0.001; fear versus tone p < 0.001). Separate paired Student’s t tests (pre-CS
versus CS) within each group reveal the ‘‘CS effect’’ (learned safety, p < 0.001; learned fear, p < 0.01; tone alone, p > 0.05).
(C) CS response after 1 day of fear conditioning in previously naive control and previously safety conditioned mice (n = 7 per group) (effect of interaction between
phase of testing and type of training: F(1,14) = 255.462, p < 0.001). ‘‘CS effect’’ (learned safety, p < 0.001; naive control, p < 0.001). Student’s t test between CS
phases (p < 0.001).
(D) CS response after 2 days of fear conditioning in previously naive control and previously safety conditioned mice (n = 7 per group) (main effect of phase of
testing F(1,14) = 47.245: p < 0.001). ‘‘CS effect’’ (learned safety, p < 0.01; naive control, p < 0.001).
(E) Contextual freezing in response to the conditioned CS and an unconditioned tone CS* (n = 7 per group) (main effect of phase of testing F(1,14) = 14.763: p < 0.01;
main effect of type of CS F(1,14) = 6.995: p < 0.05; effect of interaction F(1,14) = 21.086: p < 0.001). ‘‘CS effect’’ (CS, p < 0.001; CS*, p > 0.05). Student’s t test
between CS phases (p < 0.001).
All data are depicted as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.0001, n.s. (not significant) p > 0.05.RESULTS
TheSafety Signal Is aConditioned Inhibitor that Leads to
Reduction of Conditioned Contextual Fear and Retards
Subsequent Fear Conditioning
Safety conditioning is carried out over 3 days, one session per
day, and comprises a simple conditioned inhibition of fear para-
digm consisting of several explicitly unpaired presentations of
the aversive US and the tone CS (see Figure 1A). After safety
training, freezing (the endogenous defense response of rodents)
to the experimental context in the presence of the CS is signifi-
cantly reduced in safety-trained mice and significantly increased150 Neuron 60, 149–161, October 9, 2008 ª2008 Elsevier Inc.in fear-conditioned mice, while remaining unchanged in tone
controls (Figure 1B). This observation provides evidence for
summation, one of the two defining criteria of a conditioned
inhibitor (Rescorla, 1971). The second test that a true condi-
tioned inhibitor needs to pass is retardation. Indeed, we found
that, when mice were fear conditioned to the same CS used
beforehand in safety training, they do not show freezing to the
tone after 1 day of fear training (Figure 1C). However, with an
additional day of fear training, previously safety-conditioned
animals also learn to freeze to the CS (Figure 1D).
To further rule out nonspecific excitatory effects of the safety
signal, we tested whether a different tone (CS*) that has not
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Behavioral Antidepressant Therapy in Micebeen explicitly unpaired with the US would reduce freezing to the
context in the memory recall test. We found that the CS, but not
the CS*, reduced contextual freezing in safety-trained mice
(Figure 1E).
Learned Safety Reduces Innate Fear in the Elevated
Plus Maze
Using a within-subject control design, we tested whether the
presence of the conditioned stimulus would act to modulate
behavioral measures associated with reduced anxiety in the
elevated plus maze. We found significantly increased numbers
of open arm entries in safety-conditioned mice in the presence
of the CS (Figure 2A). Closed arm entries were significantly
decreased in safety-conditioned mice and increased in fear-
conditioned mice during delivery of the CS (Figure 2B). Moreover,
safety-conditioned mice spent significantly more time in the open
arms in the CS than in the no-CS period, whereas the opposite
effect was observed in fear-conditioned mice (Figure 2C).
Learned Safety Can Serve as a Behavioral
Antidepressant
Delivery of the Safety Signal Reduces Immobility
in the Forced-Swim Test
Immobility in the forced-swim test, interpreted as a form of be-
havioral despair, was significantly reduced in safety-conditioned
mice in the presence of the safety signal (Figure 3A). We then
evaluated, in safety-trained mice, the effect of fluoxetine on
immobility in the forced-swim test, in order to validate the antide-
pressant activity of the safety signal with respect to a widely used
pharmacological antidepressant. Vehicle- and fluoxetine-
treated mice were either exposed to the safety signal during
the forced-swim test (CS groups) or served as control (no-CS
groups). We found that the percentage of time spent immobile
in the vehicle-treated CS group and the fluoxetine-treated
no-CS group was not different, suggesting that the reduction in
immobility induced by the safety signal is comparable to the
effect seen with the antidepressant fluoxetine. Immobility was
even further decreased in the presence of the safety signal in
fluoxetine-treated safety-trained mice (Figure 3B).
Learned Safety Reduces Anhedonia Brought
on by Unpredictable Chronic Mild Stress
We found that a 4 week exposure to unpredictable chronic mild
stress induced a significantly increased response for learned
safety in the memory recall test (Figure 3C). The depressive state
induced by UCMS is associated with anhedonic behavior that
can be assessed in the sucrose preference test. As expected,
all mice showed abolished sucrose preference following
UCMS treatment. In UCMS-treated safety-trained mice, sucrose
preference was restored to levels of unstressed controls when
assessed in the presence of the safety signal. The safety signal
had no effect on sucrose preference in tone-alone controls
(Figure 3D).
Safety Learning Promotes the Survival of Newborn Cells
in the Hippocampal Dentate Gyrus
To determine whether safety learning has an effect on adult-
generated hippocampal neurons, we examined the number
Figure 2. Learned Safety Exerts Anxiolytic
Effects in the Elevated Plus Maze
(A) Open arm entries (main effect of phase of test-
ing F(1,15) = 27.668: p < 0.001; main effect of type of
training F(2,15) = 18.428: p < 0.001); effect of inter-
action between phase of testing and type of train-
ing F(2,15) = 9.354: p < 0.01; Tukey-Kramer post
hoc test for type of training (CS phase): safety
versus fear and safety versus tone p < 0.001; fear
versus tone p > 0.05). ‘‘CS effect’’ (learned safety:
p < 0.001, learned fear and tone-alone: p > 0.05).
(B) Closed arm entries (main effect of phase of test-
ing F(1,15) = 102.552: p < 0.001; main effect of type
of training F(2,15) = 6.665: p < 0.01; effect of interac-
tion between phase of testing and type of training
F(2,15) = 8.274: p < 0.01; Tukey-Kramer post hoc
test for type of training (CS phase): safety versus
fear and versus tone p < 0.001; fear versus tone
p < 0.01). ‘‘CS effect’’ (learned safety: p < 0.001,
learned fear: p < 0.01 and tone-alone: p > 0.05).
(C) Time in open arms (main effect of type of type of
training F(2,15) = 21.635: p < 0.001; effect of interac-
tion between phase of testing and type of training
F(2,15) = 65.768: p < 0.001; Tukey-Kramer post hoc
test for type of training (CS phase): safety versus
tone and versus fear p < 0.001; fear versus tone
p < 0.001). ‘‘CS effect’’ (learned safety, p < 0.001;
learned fear, p < 0.01; tone alone, p > 0.05)
(n = 7–8 per group in each case).
All data are depicted as mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.0001, n.s. (not significant)
p > 0.05.Neuron 60, 149–161, October 9, 2008 ª2008 Elsevier Inc. 151
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Behavioral Antidepressant Therapy in MiceFigure 3. Learned Safety Acts to Induce Antidepressant-like Behaviors
(A) Immobility in the presence of the CS (n = 10 per group) (main effect of phase of testing F(1,30) = 10.076: p < 0.01; interaction between phase of testing and type of
training F(1,30) = 27.243: p < 0.001). Tukey-Kramer post hoc test for type of training (CS phase): safety versus tone p < 0.05 and versus fear p < 0.001; fear versus
tone p > 0.05). ‘‘CS effect’’ (learned safety, p < 0.001; learned fear and tone alone, p > 0.05).
(B) Immobility during the CS delivery period and the corresponding time period in the no-CS groups (n = 8–9 per group) in fluoxetine- and vehicle-treated groups
(main effect of phase of testing F(1,33) = 61.190: p < 0.001; main effect of drug F(1,33) = 154.928: p < 0.001; main effect of CS delivery F(1,33) = 32.696: p < 0.001);
effect of interaction between phase of testing and drug F(1,33) = 3.859: p < 0.05; effect of interaction between phase of testing and CS delivery F(1,33) = 142.242:
p < 0.001; effect of interaction between phase of testing and drug and CS delivery F(1,33) = 5.791: p < 0.05. ‘‘CS effect’’ (vehicle CS and fluoxetine CS, p < 0.001;
vehicle no-CS and fluoxetine no-CS, p > 0.05). Student’s t test between CS phases of vehicle CS and fluoxetine no-CS p > 0.05.
(C) Safety response in the memory recall test following 4 weeks of unpredictable chronic mild stress (UCMS) (n = 9–10 per group) (main effect of phase of testing
F(1,19) = 135.903: p < 0.001; effect of interaction with UCMS exposure F(1,19) = 10.057: p < 0.01). ‘‘CS effect’’ (learned safety unstressed and learned safety UCMS:
p < 0.001). Student’s t test between CS phases of learned safety unstressed and learned safety UCMS p < 0.05).
(D) Sucrose preference 24 hr after the last day of training (values above 50% [horizontal line] indicate sucrose preference above chance) in the presence of the CS
(n = 7 per group) (main effect of UCMS exposure F(1,28) = 20.085: p < 0.001; main effect of type of training F(1,28) = 5.356: p < 0.05; effect of interaction between
UCMS exposure and type of training F(1,28) = 6.663: p < 0.05). Tukey-Kramer post hoc test: tone control UCMS versus all other groups: p < 0.01).
Data are depicted as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.0001, n.s. (not significant) p > 0.05.and the fate of newborn cells using labeling with the thymidine
analog bromodeoxyuridine (BrdU). We employed two para-
digms: the ‘‘survival paradigm’’ and the ‘‘proliferation paradigm’’
(Figure 4A) (Gould et al., 1999; Malberg et al., 2000). We found
that learned safety significantly enhanced the number of new-
born cells surviving 2 weeks after BrdU administration (Figures
4B–4E). Results from the proliferation paradigm indicate that
learned safety did not affect the rate of neurogenesis.
Ablation of Hippocampal Neurogenesis Retards Safety
Learning
We used x-irradiation of the dentate gyrus to ablate hippocampal
neurogenesis in mice and verified the absence of newly gener-
ated cells by doublecortin immunohistochemistry (a marker for
neurons younger than 1 month of age) 6 weeks later (Figure S1
available online). We then tested the effect of ablated hippocam-
pal neurogenesis on learned safety and found that x-irradiated
mice showed no evidence of safety learning after 1 day of152 Neuron 60, 149–161, October 9, 2008 ª2008 Elsevier Inc.training, in contrast to sham-irradiated control mice (Figure 5A).
However, after an additional 2 days of training, both x-irradiated
and sham mice displayed significant reduction of contextual
freezing when exposed to the safety signal (Figure 5B). In
contrast to learned safety, fear conditioning was not affected
by ablation of hippocampal neurogenesis on either day.
Ablation of Neurogenesis Inhibits the Antidepressant
Action of Learned Safety
When evaluating the potential of learned safety to reduce de-
pression-like behaviors, we found that safety trained x-irradiated
mice did not show reduced immobility in the presence of the
safety signal, which was observed in the controls (Figure 5C).
Moreover, UCMS-induced enhancement of the safety response
was absent (Figure 5D), and the ability of learned safety to rescue
the UCMS-induced reduction of sucrose preference was
abolished in x-irradiated safety-trained mice (Figure 5E).
Neuron
Behavioral Antidepressant Therapy in MiceFigure 4. Learned Safety Promotes the Survival of Newborn Cells in the Dentate Gyrus of the Hippocampus
(A) In the ‘‘survival paradigm,’’ BrdU was injected 3 days prior to behavioral training. Mice were sacrificed 14 days after the first BrdU injection. In the ‘‘proliferation
paradigm,’’ BrdU was injected starting 2 hr after the last behavioral training, and mice were sacrificed 24 hr later. (B) Number of BrdU-labeled cells in the dentate
gyrus in the survival paradigm. Confocal laser-scanning microscopic images (103) of BrdU-labeled cells (light blue) reveal a significant difference in number
between (C) tone-alone control, (D) fear-conditioned, and (E) safety-conditioned mice (n = 4 per group) (F(2,15) = 5.650: p < 0.01, Tukey-Kramer post-hoc test
safety versus tone p < 0.01, safety versus fear p < 0.05). (F) The vast majority of BrdU-labeled cells (red-yellow) were immunoreactive for the neuronal marker
NeuN (603). Data are depicted as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.0001, n.s. (not significant) p > 0.05.Safety Learning Increases Expression of BDNF
in the Dentate Gyrus of the Hippocampus
BDNF is known to be induced by antidepressant treatment in the
hippocampus, particularly in the dentate gyrus (Nibuya et al.,
1995; Russo-Neustadt et al., 2004), and could be responsible
for the increase in and survival of hippocampal neurons following
antidepressant drug treatment (Duman, 2004a, 2004b). This led us
to analyze the expression of BDNF in the dentate gyrus in mice fol-
lowing safety and fear training together with tone-alone controls.
Using immunohistochemical analysis, we found increased BDNF
expression in safety-conditioned mice, whereas the expression
of BDNF in fear-conditioned mice was reduced as compared to
tone-alone controls (Figure 6).
Genes Differentially Expressed in the Basolateral
Amygdala of Safety-Conditioned and Fear-Conditioned
Mice
To characterize the molecular mechanisms involved in safety
learning, we searched for genes whose mRNAs were differen-
tially regulated in safety- and fear-conditioned mice in the
basolateral nucleus of the amygdala. We isolated the basolateral
nucleus of the amygdala using laser-capture microdissection
(LCM), which permits for rigorously controlled and precise isola-
tion of the target nucleus without contamination from surround-
ing areas (Figure 7A). Using a combination of hypothesis-free
and hypothesis-driven approaches, we examined all significantchanges (80 specific probe sets) (Figure 7B and Table S1) but
thereafter also focused on certain candidate genes that have
been implicated in the literature to be involved in stress, anxiety,
and depression (Table S2).
We found differential regulation of four genes (dopamine D2
receptor, substance P, prodynorphin, and preproenkephalin 1)
that have been highly implicated in the response to endogenous
and exogenous stressors and depression (McLaughlin et al.,
2003; Sinchak et al., 2000). To independently verify the observed
changes and to relate them to benchmark values, we carried out
RT-PCR analyses for two of these genes—dopamine D2 recep-
tor (D2R) and substance P (SP)—those on which we focused
more in subsequent experiments. In addition, RNA isolated
from LCM samples of handled-only mice as naive baseline
controls was included (Figures 7C and 7D).
Blocking D2 Receptors Facilitates the Memories
for Learned Safety
To evaluate the importance of the gene expression findings
in vivo, we examined the effects of blockade of D2R on the
memory for learned safety. We found that the treatment with
the D2R antagonist sulpiride before the memory recall test led
to a significant enhancement of the safety response (Figure 8A).
When sulpiride was administered before the training sessions
and mice were tested drug free, no effect in either safety- or
fear-trained mice was observed (Figure S2A).Neuron 60, 149–161, October 9, 2008 ª2008 Elsevier Inc. 153
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recall test (Figure 8B) but not before the training sessions
(Figure S2B) abolished the safety response in the memory recall
test. Quinprinole treatment did not affect learned fear under
either condition.
A significant interaction between CS delivery and drug admin-
istration was revealed when we trained mice drug free in the
learned safety paradigm and administered sulpiride before the
forced-swim test. This result suggests that dopaminergic trans-
mission is an important, although not the exclusive, mediator of
learned safety (Figure 8C).
Blocking NK-1 Receptors Facilitates the Acquisition
of Learned Safety
To determine the importance of Substance P in vivo, we first
tested the effect of blockade of the preferred receptor for Sub-
stance P, the NK-1 receptor, using L-703,606. We found that
the response to the safety CS was not different in L-703,606-
treated and vehicle-treated mice in both safety- and fear-
conditioned mice when mice were trained drug free and NK-1
receptors were blocked only during the memory recall test (Fig-
ure S2C). However, when we trained mice under the influence of
L-703,606 and then tested them drug free, we observed a signif-
icantly enhanced safety response in L-703,606-treated mice
whereas the response to the CS was not altered in fear-condi-
tioned mice. NK-1 inhibition during training did not affect the
CS response in the memory recall test (Figure 8D). Application
of the NK-1 agonist ([Sar9, Met(O2)11]-Substance P) before
the memory recall test did not affect learned safety (Figure S2D).
However, when we exposed the animals to the NK-1 agonist
before each training session, we observed a reduced safety
response during the memory recall test (Figure 8E). The learned
fear response was not affected by drug treatment under either
condition.
Figure 5. Ablation of Hippocampal Neurogenesis Retards Safety Learning and Inactivates the Antidepressant Effect of the Safety Signal
(A) Safety response in x-irradiated mice and sham-irradiated controls after 1 day of training (n = 7 per group) (main effect of phase of testing F(1,32) = 5.477: p <
0.05; effect of interaction between phase of testing and type of training F(1,32) = 58.152: p < 0.001 and phase of testing and x-irradiation F(1,32) = 8.863: p < 0.01 and
phase of testing and of type of training and x-irradiation F(1,32) = 4.957: p < 0.05). ‘‘CS effect’’ (learned safety sham and learned fear X-ray: p < 0.001; learned fear
sham: p < 0.01; learned safety X-ray: p > 0.05).
(B) Safety response in x-irradiated mice and sham-irradiated controls after 3 days of training (n = 7 per group) (effect of interaction between phase of testing and
type of training F(1,32) = 58.152: p < 0.001 and phase of testing and x-irradiation F(1,28) = 59.917: p < 0.001). ‘‘CS effect’’ (all groups: p < 0.001).
(C) Immobility during the presentation of the CS compared to the time period without the CS (no-CS) (n = 8–9 per group) (main effect of type of training F(1,35) =
5.877: p < 0.05; effect of interaction between phase of testing and type of training F(1,35) = 16.311: p < 0.001 and phase of testing and type of training and x-ir-
radiation F(1,35) = 4.220: p < 0.05). ‘‘CS effect’’ (learned safety sham: p < 0.001: all other groups p > 0.05).
(D) Safety response in x-irradiated and sham-irradiated control mice after 4 weeks of UCMS (n = 7–8 per group) (main effect of phase of testing F(1,22) =
149.976: p < 0.001; interaction between phase of testing and x-irradiation F(1,22) = 6.469: p < 0.05; interaction between phase of testing and x-irradiation
and UCMS exposure F(1,22) = 7.707: p < 0.05; interaction between UCMS exposure and x-irradiation F(1,22) = 5.257: p < 0.05). ‘‘CS effect’’ (all groups:
p < 0.001). Student’s t test between CS phases of unstressed sham and UCMS sham: p < 0.05; CS phases of unstressed X-ray and UCMS X-ray:
p > 0.05.
(E) Sucrose preference in the presence of the CS in x-irradiated and sham-controls after UCMS or no-stress control (n = 5–7 per group) (main effect of UCMS
treatment F(1,43) = 33.988: p < 0.01; interaction between type of training and UCMS treatment F(1,43) = 12.088: p < 0.01; interaction between type of training and
UCMS treatment and x-irradiation F(1,43) = 6.027: p < 0.05). Student’s t test between CS phases of safety UCMS sham and safety UCMS X-ray: p < 0.01. Data are
depicted as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.0001, n.s. (not significant) p > 0.05.154 Neuron 60, 149–161, October 9, 2008 ª2008 Elsevier Inc.
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Learning
Several lines of evidence support an important role of 5-HT1A
receptors in depressive illness (Bowen et al., 1989; Drevets et al.,
1999) and in the response to antidepressants (Li et al., 1998;
Singh and Lucki, 1993). However, blockade of 5-HT1A receptors
affected learned safety neither in the acquisition nor in the
memory recall phase (Figures 8F and 8G).
DISCUSSION
We find that learned safety reduces depression-like behavior in
mice. Consistent with its behavioral antidepressant effects,
learned safety enhances the survival of newborn cells and leads
to increased expression of BDNF in the hippocampal dentate
gyrus. In the amygdala, learned safety strongly modulates the
expression of key components of the dopaminergic and
neuropeptidergic system while having no effect on elements of
the serotonergic transmission. Learned safety thus exerts its an-
tidepressant activity through cell-biological steps also recruited
by conventional, serotonergically based antidepressants but
triggers these through different molecular pathways.
Learned Safety Reduces Learned Contextual
and Unlearned, Innate Fear
We produced learned safety by a conditioned inhibition of fear
protocol in which the animal learns about a stimulus—the safety
signal—that indicates the absence of impending aversive
events. We and others have found that the behavioral response
triggered by the safety signal can become independent from the
context in which it has been acquired and might even be effec-
tive to control a different, unconditioned response (Denniston
et al., 1998; Rogan et al., 2005). We now find that the safety sig-
nal in itself contains an autonomous informational content that
can be transferred and lead to reduction in unlearned, innate
fear in the elevated plus maze.
Learned Safety Reduces Depression-like Behavior
in Two Animal Models
We used two animal models of depression to test the idea that
the safety signal may come to indicate a general ‘‘relief period’’
from ongoing stress and thus may counteract depressive states.
We found an antidepressant effect in the forced-swim test
(similar and in magnitude comparable to pharmacological
treatment with fluoxetine) and complemented this result by the
rescue of chronic mild stress-induced reduction in sucrose
preference by the safety signal, similar to that obtained with
pharmacological antidepressants (Gittos and Papp, 2001;
Moreau et al., 1996).
Antidepressant pharmacotherapy is more effective in patients
with depressive disorders than in healthy controls. The enhance-
ment of the learned safety response in mice, in which a depres-
sive state has been induced by chronic mild stress, resembles
this situation in humans and supports learned safety as an animal
model of behavioral antidepressant treatment with good face
and content validity.
Learned Safety Shares Neurobiological Hallmarks
of Pharmacological Antidepressants
Many pharmacological antidepressants and other interventions
achieving antidepressant effects increase neurogenesis,
whereas, conversely, stress typically reduces neurogenesis
(Warner-Schmidt and Duman, 2006; Dranovsky and Hen, 2006;
Malberg and Duman, 2003). We found that in the ‘‘survival para-
digm’’ learned safety enhances the number of BrdU-positive
cells in the dentate gyrus 14 days after BrdU labeling. The num-
ber of new cells in the dentate gyrus increases between 2 hr and
1 week after DNA synthesis and then declines rapidly by the 2
week time point (Cameron et al., 1993). The ability of learned
safety to rescue cells that were generated shortly before the
training procedure provides a direct link between newborn cells
in the adult hippocampus and this behavioral paradigm. These
results on neurogenesis add further significance to the
Figure 6. Learned Safety Leads to In-
creased Expression of BDNF in the Dentate
Gyrus of the Hippocampus
Dentate gyrus BDNF immunohistochemistry in
mice sacrificed 4 hr after the last day of behavioral





(D) Statistical analysis revealed increased levels of
BDNF in safety-conditioned and decreased levels
in fear-conditioned mice (n = 4 per group) (F(2,15) =
42.423: p < 0.001; Tukey-Kramer post hoc test;
safety versus fear and tone p < 0.001; fear versus
tone p < 0.01).
Data are depicted as mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.0001, n.s. (not significant)
p > 0.05.Neuron 60, 149–161, October 9, 2008 ª2008 Elsevier Inc. 155
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learned safety. The fact that we observed an enhanced survival
of those cells that were generated before training but did not ob-
serve an effect when BrdU was injected after training suggests
that the effect of learned safety on newborn cells may occur
only during a specific ‘‘sensitive period’’ following the generation
of these cells. Interestingly, it is precisely within this time frame
(between 1 and 2 weeks after mitosis) that adult-generated gran-
ule cells of the dentate gyrus appear to be forming connections
with the CA3 region (Gould et al., 1999). Learned safety, thus,
may facilitate the integration of these cells into an established
circuitry and promote their survival.
Another factor potentially contributing to enhanced cell sur-
vival following learned safety may be the increased neurotrophic
support by BDNF. BDNF has been shown to be regulated by
antidepressant and is thought to oppose the effects of stress
on neuronal cells (e.g., inhibiting excitotoxic damage, blocking
neuronal atrophy, etc.) by helping to make neurons more resilient
to stress and by maintaining basal levels of hippocampal neuro-
genesis (Nibuya et al., 1995).
The delayed acquisition of learned safety in mice with ablated
hippocampal neurogenesis shows that neurogenesis is impor-
tantly involved in, although not the only process required for, the
acquisition of learned safety. For the behavioral antidepressant
effects, however, neurogenesis seems to be more essential, since
the response to the antidepressant activity of the safety signal in
the forced-swim test and the sucrose preference test was blunted
in mice with ablated hippocampal neurogenesis. This result is also
in agreement with other studies demonstrating ineffectiveness of
pharmacological antidepressants in mice with ablated hippocam-
pal neurogenesis (Manev et al., 2001; Santarelli et al., 2003).
Learned Safety Acts through Molecular Mechanisms
Distinct from Conventional Pharmacological
Antidepressants
In the search for the molecular basis for the behavioral character-
istics and functional properties of learned safety, we turned
toward the amygdala, where we have previously identified dis-
tinct neural changes in safety-trained mice (Rogan et al., 2005).
We focused on two candidate systems: the dopaminergic and
Figure 7. Laser-Capture Microdissection Enables Precise Isolation of the Mouse Basolateral Amygdala for Subsequent Gene Expression
Analysis
(A) Firing an infrared laser through a thermoplastic cap leads to the melting of the target tissue with the cap. When the cap is lifted, the tissue is removed from the
tissue section and remains attached to the cap from where RNA can be isolated and used for molecular analysis. (B) Hierarchical clusters of genes regulated by
learned safety in the mouse basolateral amygdala (in comparison to fear conditioning controls). Relative expressional changes are colored coded using a heat
map with red-to-blue gradient depicting an up- to downregulation (R2-fold increase/%2-fold decrease). mRNA expression of (C) D2R, (D) SP in basolateral
amygdala samples of safety-trained, fear-trained, and handled-only (naive control) mice as evaluated by RT- PCR. Values normalized to the expression of GAPDH
are displayed (n = 5–6 per group). (D2R: F(2,16) = 7.623: p < 0.01, Tukey-Kramer post hoc test safety versus handled only and safety versus fear p < 0.01; SP:
F(2,16) = 5.088: p < 0.01, Tukey-Kramer post hoc test safety versus handled only and safety versus fear p < 0.05). All data are depicted as mean ± SEM. *p < 0.05,
**p < 0.01, ***p < 0.0001, n.s. (not significant) p > 0.05.156 Neuron 60, 149–161, October 9, 2008 ª2008 Elsevier Inc.
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ulated by dopaminergic inputs, which are central for mediating
physiological and pathological responses to positive and nega-
tive stimuli. Moreover, in animal models of depression, stress
has been found to activate the midbrain dopaminergic system
by stimulating dopaminergic transmission from the ventral teg-
mental area (VTA) to its limbic targets, including the amygdala
(Di Chiara et al., 1999; Horger and Roth, 1996). Our finding that
sulpiride reduces behavioral despair in the forced-swim test is
in agreement with reports on the antidepressant effects of
Figure 8. Dopamine D2 Receptor and Substance P but Not 5-HT1A Receptors Are Critically Involved in Learned Safety
(A) Effect of sulpiride administration before the memory recall test (n = 7–9 per group) (main effect of phase of testing F(1,35) = 5.223: p < 0.05; main effect of type of
training F(1,35) = 17.430: p < 0.001; interaction between phase of testing and type of training F(1,35) = 181.482: p < 0.001; interaction between phase of testing and
drug F(1,35) = 5.018: p < 0.05; interaction between phase of testing and type of training and drug F(1,35) = 5.163: p < 0.05). ‘‘CS effect’’ (all groups: p < 0.001).
Student’s t test between CS phases of learned safety vehicle versus learned safety sulpiride: p < 0.05).
(B) Effect of quinprinole administration before the memory recall test (n = 7–9 per group) (interaction between phase of testing and type of training F(1,36) = 22.276:
p < 0.001; interaction between phase of testing and drug F(1,36) = 5.113: p < 0.05; interaction between phase of testing and type of training and drug F(1,40) = 8.445:
p < 0.01). ‘‘CS effect’’ (learned safety vehicle: p < 0.001; learned safety quinprinole: p > 0.05; learned fear vehicle: p < 0.01, learned fear quinprinole: p < 0.05).
(C) Effect of treatment with sulpiride prior to the forced-swim test (n = 7–8 per group) (effect of phase of testing F(1,15) = 44.176: p < 0.001; interaction between
phase of testing and drug F(1,15) = 5.932: p < 0.05). ‘‘CS effect’’ (learned safety vehicle, p < 0.05; learned safety sulpiride, p < 0.001). Student’s t test between CS
phases of learned safety vehicle versus learned safety sulpiride: p < 0.001.
(D) Effect of blockade of NK-1 receptors by L703,606 during safety training on response to the CS in the memory recall test (n = 8–9 per group) (main effect of
phase of testing F(1,35) = 5.734: p < 0.05; main effect of type of training F(1,35) = 8.899: p < 0.01; effect of interaction between phase of testing and type of training
F(1,35) = 118.869: p < 0.001; effect of interaction between phase of testing and drug F(1,35) = 4.692: p < 0.05; effect of interaction between phase of testing and type
of training and drug F(1,35) = 5.644: p < 0.05). ‘‘CS effect’’ (learned safety vehicle: learned safety L703,606, learned fear L703,606: p < 0.001; learned fear vehicle:
p < 0.01). Student’s t test between CS phases of learned safety vehicle versus learned safety L703,606: p < 0.001.
(E) Effect of administration of a NK-1 agonist ([Sar9, Met(O2)11]-Substance P) during training on the CS response in the memory recall test (n = 8 per group) (effect
of interaction between phase of testing and type of training F(1,32) = 8.357: p < 0.01; effect of interaction between phase of testing and type of training and drugF(1,32) =
26.249: p < 0.001). ‘‘CS effect’’ (learned safety vehicle, learned fear vehicle, learned fear ([Sar9, Met(O2)11]: p < 0.001; learned safety ([Sar9, Met(O2)11]: p > 0.05).
(F) Effect of blockade of 5-HT1A receptors by WAY-100635 during training on the response to the CS in the memory recall test (n = 8 per group) (main effect of
phase of testing F(1,32) = 8.887: p < 0.01; effect of interaction between phase of testing and type of training F(1,32) = 18.873: p < 0.001). ‘‘CS effect’’ (learned safety
vehicle, learned fear WAY-100635: p < 0.01; learned safety WAY-100635, learned fear vehicle: p < 0.001).
(G) Effect of administration of WAY-100635 before the memory recall test (n = 8 per group) (main effect of phase of testing F(1,32) = 10.098: p < 0.01; effect of
interaction between phase of testing and type of training F(1,32) = 43.337: p < 0.001). ‘‘CS effect’’ (learned safety vehicle, learned safety WAY-100635, learned
fear WAY-100635: p < 0.001; learned fear vehicle: p < 0.01). All data are depicted as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.0001, n.s. (not significant) p > 0.05.Neuron 60, 149–161, October 9, 2008 ª2008 Elsevier Inc. 157
Neuron
Behavioral Antidepressant Therapy in Miceamisulpiride in rats (Papp and Wieronska, 2000) and in humans
(for review see Jarema, 2007). Downregulation of D2R in the
course of safety training may act to reduce or relieve the experi-
ence of stress and thereby contribute to the antidepressant
potential of learned safety.
The parallel regulation of Substance P together with D2R is
consistent with a bidirectional feedback mechanism between
the two neurotransmitter systems that is thought to be important
in mediating associative learning and emotional responses has
been recently demonstrated (Kovacs et al., 2006).
We propose a model in which the stress-reducing and antide-
pressant effects of learned safety are mediated through the
interaction of (at least) two different transmitter systems, leading
to neuronal modifications typical of pharmacological antidepres-
sant treatment. Stress relief, as a consequence of learned safety,
may reduce the firing of dopaminergic cells of the VTA, which in
turn leads to downregulation of D2R in the basolateral amygdala.
Reduction of dopamine may then inhibit the expression of
Substance P mRNA (Kovacs et al., 2006). Reduced levels of
Substance P may then feed back to further reduce the activation
of the midbrain dopaminergic system (Renoldi and Invernizzi,
2006) and in part, indirectly through increased expression of
BDNF, provide enhanced neurotrophic support to promote the
survival of newborn cells in the hippocampus (Morcuende et al.,
2003).
In summary, our findings make three main points. One, learned
safety represents an animal model of a behavioral intervention
for depression that leads to behavioral outcomes similar to
pharmacological interventions. Two, learned safety induces cell-
biological changes known to result from antidepressant pharma-
cotherapy but is mediated through different molecular pathways.
Three, learned safety may provide a paradigm for the screening
of pharmacological targets for the treatment of depressive




Male C57BL6/N mice (10–12 weeks old) (Charles River Laboratories, Willing-
ton, MA) were used for all experiments. Mice were kept in clear plastic cages
with ad libitum food and water, unless otherwise described. All animal proce-
dures described were executed in accordance with National Institute of Health
regulations and approved by the institutional Animal Care and Use Commit-
tees of Columbia University and the New York State Psychiatric Institute.
Behavioral Training and Testing
Animals were handled daily for 3 days prior to the safety- or fear-training
procedure. In case of the pharmacology experiments, mice were injected
i.p. with saline in the course of each of these handling sessions. All behavioral
conditioning paradigms and control protocols were carried out over 3 days,
followed by a test day 24 hr after the last training day. Training for all animals
occurred in behavioral chambers (MED Associates, VT) housed within a
soundproof box.
Safety conditioning consisted of four explicitly unpaired US and CS presen-
tations (one session per day for 3 days). The fear conditioning protocol was
matched to the number of auditory CS and shock US presentations of the
safety conditioning paradigm and thus constituted four paired CS-US presen-
tations per day (see Figure 1A for details). In tone-alone controls, four CS were
delivered at the same time points as in the safety conditioning protocol. The
precise timing of stimuli varied within session and across days. A memory158 Neuron 60, 149–161, October 9, 2008 ª2008 Elsevier Inc.recall test, consisting of the sole presentation of one CS (20 s), was carried
out 24 hr after the last training day. In any instance, the behavior during the
CS period (20 s) was compared to the corresponding length of time (20 s) prior
to the onset of the CS (pre-CS period). For the fear conditioning retardation
test, previously safety-conditioned mice were trained in a simple fear condi-
tioning paradigm (consisting of three CS-US pairings) starting 24 hr after the
last day of safety training. Control mice were naive (handled only) prior to
fear conditioning. Freezing to the tone was evaluated on the following day in
a novel context. In each instance, the US was a scrambled footshock
(0.6 mA) delivered for 2 s through the bars of the conditioning chamber. The
CS was a software-generated 350 Hz pulsed tone (2 ms rise time, 2% duty
cycle) at 72 dB with a total duration of 20 s. For the differential tone testing,
the second, unconditioned tone was a software-generated 50 Hz steady
tone at 72 dB with a total duration of 20 s. For this experiment, mice were
exposed to four presentations of the CS* after the handling period (day 4).
All freezing behavior was evaluated by digital video recordings analyzed with
FreezeFrame software (Actimetrics, Evanston, IL).
Forced-Swim Test
The forced-swim test was carried out as described elsewhere (Dulawa et al.,
2004). The last 4 min of the 6 min test were scored by analysis of videotapes
for immobility. To evaluate the effects of the delivery of the auditory CS on
immobility in conditioned mice, the CS was presented during minutes 4 and
5. The time spent immobile during these 2 min was averaged and compared
to the average of the time spent immobile during minutes 3 and 6.
Unpredictable Chronic Mild Stress
The protocol to induce UCMS was adapted from Goshen et al. (2007).
X-irradiated and sham control mice were allowed a 5 week recovery period
before being subjected to the UCMS protocol.
Sucrose Preference Test
The sucrose preference test was modified from Yu et al. (2007). Twelve hours
after exposure to the last stressor of the UCMS regime, animals were deprived
of food and water and tested for sucrose preference 23 hr later. Testing was
carried out in the home cage in the form of a two bottle choice paradigm
(2% sucrose versus water) in the presence of the CS for 1 hr. Sucrose prefer-
ence rate was calculated according to the formula: % preference = [(sucrose
intake/total intake) 3 100%].
Elevated Plus Maze
The elevated plus maze test was carried out as described (Shumyatsky et al.,
2002). During the 5 min of testing, the auditory CS was delivered during
minutes 3 and 4, and the time spent (in seconds) and entries in the different
compartments (closed and open arms) were averaged and compared to the
average of the no-CS period (minutes 2 and 5).
Pharmacology
Chemicals
All drugs were purchased from Sigma Aldrich (Sigma, St. Louis, MO). Sulpiride
was dissolved in 0.9% physiological saline and was adjusted to a neutral pH.
L703,606 was dissolved in 0.9% physiological saline and 0.5% v/v DMSO.
Fluoxetine was dissolved in distilled water. WAY100635, quinprinole, and
[Sar9, Met(O2)11]-Substance P were dissolved in 0.9% physiological saline.
Drug Administration
Sulpiride (20 mg/kg) was injected 45 min, L703,606 (1 mg/kg), WAY100635
(1 mg/kg), and quinprinole (0.1 mg/kg) were injected 30 min, and [Sar9,
Met(O2)11]-Substance P (0.5 mg/kg) was injected 20 min prior behavioral
experiments. For the forced-swim test, fluoxetine (15 mg/kg) was injected in
a repeated-injection schedule at 24 hr, 5 hr, and 1 hr prior to the forced-
swim test. All drugs were injected i.p., and the final injection volume was
5 ml/kg in each case.
X-Ray Irraditation Procedure
Mice received fractionated low-dose x-irradiation to the head, as previously
described (Santarelli et al., 2003).
Doublecortin Immunohistochemistry
Doublecortin immunohistochemistry was performed as previously described
(Holick et al., 2008).
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Mice were administered BrdU (50 mg/kg i.p.) [(+)-50 bromo-20-deoxyuridine;
97%; Sigma, St. Louis, MO] twice per day (8 hr interval) for 3 days prior to
safety or fear conditioning and sacrificed 14 days after the first BrdU injection
for assessment of survival of the newborn cells (‘‘survival paradigm’’). For
assessment of stimulation of neurogenesis, BrdU was administered four times
(every 2 hr) starting 2 hr after termination of safety or fear conditioning, and
mice were sacrificed 24 hr after the last BrdU injection (‘‘proliferation
paradigm’’). After anesthesia with ketamine/xylazine, mice were transcardially
perfused with 4% paraformaldehyde (PFA) in 0.1 M phosphate-buffered saline
(PBS; pH 7.4). Brains were collected and postfixed overnight in 4% PFA at 4C.
The following day, serial coronal sections (30 mm) along the entire rostrocaudal
extension of the hippocampus were cut on a vibratome and stored in a cryo-
protective solution (30% ethylene glycol, 30% glycerol in 0.1 M PBS) at 20C
until further processed. BrdU immunohistochemistry was performed on every
tenth free-floating section (n = 4 per group), essentially as described elsewhere
(Wojtowicz and Kee, 2006).
BDNF Immunofluorescence
Animals were sacrificed 4 hr after the last day of training, and brains were pro-
cessed as described above for BrdU analysis. BDNF immunohistochemistry
was performed on every sixth section from each animal (n = 4 per group). Sec-
tions were rinsed in 0.1 M PBS (at pH 7.4) before incubating for 1 hr in blocking
solution (0.1 M PBS, 0.3% Triton X-100, 10% fetal bovine serum). Sections
were then incubated with a monoclonal anti-human BDNF antibody (Promega,
Madison, WI) overnight at 4C on a shaker. The following day, sections were
rinsed in 0.1 M PBS (at pH 7.4) and incubated for 1 hr with a secondary anti-
body (Alexa Fluor 647 goat anti-human IgG [H+L]; Molecular Probes, Invitrogen
Corporation, Carslbad, CA). After rinsing in 0.1 M PBS, sections were dried
and coverslipped (Fluorosave; Calbiochem, La Jolla, CA).
Imaging and Quantification of BrdU, BrdU/NeuN, and BDNF
Immunofluorescence
Hippocampal BrdU labeling was quantified according to a modified unbiased
stereology protocol by an experimenter blind to the experimental condition
(Gould et al., 1999; West et al., 1991). Confocal images were acquired using
an Olympus Fluoview FV1000 scanning module with an Olympus IX81
microscope (Olympus America, Center Valley, PA). BrdU/NeuN double
labeling was carried out essentially as described elsewhere (Meshi et al.,
2006). Quantification of BDNF immunofluorescence intensity was performed
according to a published method (Gazzaley et al., 1996).
Gene Expression Analysis
Brain Dissection
Animals were sacrificed by cervical dislocation 4 hr after the last training day.
Brains were rapidly dissected out, snap-frozen, and stored at 80C until
needed. Eight micrometer brain sections were sliced with a cryostat and
immediately stored at 80C in a dry container.
Laser Capture Microdissection
A total of three coronal sections of the amygdala per animal (n = 5 per group)
were subjected to LCM. The left and right basolateral nucleus of the amygdala
of sections from the rostral (Bregma 0.82 mm), medial (Bregma 1.34 mm),
and caudal (Bregma 1.82 mm) amygdala were used for LCM. Brain sections
were removed from 80C and immediately dehydrated in a gradient alcohol
series and a final incubation in xylene for clearance. Sections were then air-
dried under a laminar flow and immediately used for LCM. LCM was carried
out using a PixCell II system (Arcturus Bioscience Inc., Mountain View, CA).
Selected regions were lifted onto CapSure LCM plastic caps (Arcturus Biosci-
ence Inc.) using a spot size of 15 mm, a laser power of 50 mV, and a duration of
2 ms. Caps with transfer films with the microdissected tissue were immediately
placed into Eppendorf tubes containing lysis buffer, incubated at 37C for
30 min, and stored in 80C before RNA isolation. Total RNA was extracted
from samples collected by LCM caps using RNAqueous-Micro Kit (Ambion
Inc., Austin, TX) including DNase treatment to remove potential genomic
DNA contamination according to the manufacturer’s instructions.Microarray Experiments
Two rounds of linear amplification were carried out using the GeneChip Two-
Cycle Target Labeling kit (Affymetrix Inc., Santa Clara, CA) according to the
supplier’s instruction. cRNA samples derived from single animals were hybrid-
ized in recommended buffers to microarrays (Affymetrix GeneChip Mouse
Genome 430A 2.0 Array). The samples were stained and washed according
to the manufacturer’s protocol on a Fluidics Station 400 (Affymetrix Inc.) and
scanned on a GeneArray Scanner (Affymetrix Inc., Santa Clara, CA). Primary
data extraction was performed with Microarray Suite 5.0 (Affymetrix Inc.,
Santa Clara, CA). Data were filtered and sorted by a sequential analysis using
GeneSpring GX 7.3 software (Affymetrix Inc., Santa Clara, CA). Briefly, raw
values were normalized using the GCRMA algorithm (Lim et al., 2007), filtered
for 2-fold expressional changes, and subjected to statistical analysis using
a nonparametric using two-way analysis of variance. Genes with significant
effects were selected by adjusting the resulting p values for multiple testing
by means of the false discovery rate using the linear step-up procedure (BH)
of Benjamini and Hochberg (Reiner et al., 2003).
Reverse Transcriptase-PCR
Total RNA was diluted to a final concentration of 100 ng/ml and reverse
transcribed using the SuperScript First-Strand synthesis system for RT-PCR
(Invitrogen Corporation, Carlsbad, CA) following the supplier’s manual. Two
microliters of the RT reaction was subjected to PCR amplification using the
AccuPrime DNA polymerase system (Invitrogen Corporation, Carlsbad, CA)
following the supplier’s manual. The primer pairs for the dopamine D2 recep-
tor, substance P, and GAPDH and respective amplification conditions were
based upon published protocols (Ding et al., 2007; Mutiara et al., 2006; Silva
et al., 2006). PCR products were separated by electrophoresis on a 1.5% aga-
rose gel and stained with ethidium bromide. Band signals were analyzed and
quantified by densitometry analysis using the Kodak Gel Logic 100 imaging
system and software. Relative intensities were calculated by normalization
to the band intensity levels of GAPDH.
Data Analysis
For analyses of all behavioral experiments involving comparisons between the
CS and the pre/no-CS period, repeated-measures ANOVAs were used, with
phase of testing as the repeated measure (within-subject factor). Type of
training, drug, or UCMS were between-subject factors. Significant main
effects or interactions were followed by Tukey-Kramer post hoc tests or paired
or unpaired two-tailed Student’s t tests where appropriate. For the sucrose
preference test, 2 (X-ray: sham or x-irradiated) 3 2 (type of training: safety
or control) 3 2 (stress: UCMS or control; for the experiment involving x-irradi-
ated mice) ANOVAs were performed. Histological and RT-PCR data were
analyzed using one-way ANOVA followed by Tukey-Kramer post hoc tests
for pair-wise comparisons for significant ANOVA results. A a level of 0.05
was adopted in all instances. All analyses were carried out using StatView
software (SAS Institute, Cary, NC).
SUPPLEMENTAL DATA
The Supplemental Data include figures and tables and can be found with this
article online athttp://www.neuron.org/supplemental/S0896-6273(08)00746-0.
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